Phase 2 N=32 Sequential Vaccinations in Prostate Cancer Patients
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer
Prostate Cancer
Primary: Change in the Number of Infiltrating CD3+ T Cells Within the Prostate Tissue Between the Biopsy and the Post-RP Tissue Specimens in Each Subject — 2.33; 2.03; 1.98; 6.39…
Phase 2 N=32 Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Primary: Number of Participants With Stable, Decreased, or Increased PSA Doubling Times (PSADT) — 7; 2; 17 Participants
Phase 2 N=8 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
Phase 3 N=1,589 Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
Preneoplastic Conditions · Prostatic Intraepithelial Neoplasia
Primary: Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN) — 54.9; 59.5 % of participants cancer-free…
Phase 2 N=36 PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
Prostate Cancer
Primary: Diagnostic Accuracy of PSMA PET — 100; 74 percentage
N/A N=408 Prostate Cancer Screening Trial Using Imaging
Prostate Neoplasm
Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants
Phase 2 N=50 Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21
Recurrent Prostate Cancer
Primary: Number of Participants Who Develop a Strong or Modest Anti-PSA Immune Response — 12; 14; 6; 3 participants
Phase 3 N=98 Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
Hormone-Refractory Prostate Cancer
Primary: Overall Time to Disease Progression — 10.9; 9.9 Weeks — p=0.719
Phase 2 N=59 Metformin Prostate Cancer Adjuvant Trial
Prostate Cancer · Prostate Cancer Recurrent
Primary: Mean Prostate Specific Antigen (PSA) Level — 0.61; 0.70; 0.54 ng/mL
Phase 2 N=16 Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 2; 6; 3 Participants
Phase 2 N=13 Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
Cancer of Prostate · Cancer of the Prostate · Neoplasms, Prostate
Primary: Percentage of Patients to Successfully Generate and Administer the Alpha-DC1 Vaccine — 100; 100 percentage of participants
Phase 2 N=80 Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…
Phase 2 N=118 Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Prostate Cancer
Primary: Combined pCR or MRD Rate [Part 1] — 12; 12 Participants
Phase 2 N=20 PSMA Imaging of Localized Prostate Cancer
Prostate Cancer
Primary: The Number of Subjects With PSMA-positive (Prostate-specific Membrane Antigen) "Dominant" PC Lesion(s) Greater Than 5mm in Diameter, Whose Lesion(s) Have Been…
Phase 2 N=1 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T
Prostate Cancer
Primary: Overall Survival
Phase 2 N=154 PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Stage I Prostate Adenocarcinoma AJCC v7 · Stage II Prostate Adenocarcinoma AJCC v7
Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2
Phase 2 N=13 Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Prostate Cancer
Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants
Phase 2 N=75 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Prostate Adenocarcinoma · Prostate Cancer · High Risk Prostate Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151
Phase 1 N=14 A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer
Prostate Cancer
Primary: Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation) — 6; 0 Participants
N/A N=35 Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study
Prostate Cancer
Primary: Feasibility - Recruitment — 39 Participants
Phase 2 N=24 PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Clinically Important Immune-related Adverse Events (for the Lead-In Cohort) — 1; 1; 1; 1 Participants
Phase 2 N=104 Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
Prostate Cancer
Primary: Number of Participants Who Received At Least 1 Infusion of Sipuleucel-T in Men With Metastatic Castrate-resistant Prostate Cancer (CRPC) — 98 participants
N/A N=64 High Resolution MRI Study for Prostate Cancer
Prostate Cancer
Primary: Sensitivity and Specificity of High Resolution Versus Standard MRI in Identifying Adverse Histology — 75; 71; 84; 54.8 percent
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 3 N=2,980 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
Breast Cancer
Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33
Phase 3 N=298 Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
Prostate Cancer
Primary: Number of Participants With Progression-Free Survival — 66; 84 Participants — p=0.40
Phase 2 N=74 Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
Prostate Cancer · Prostate Neoplasms · Neoplasms, Prostatic
Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale
Phase 2 N=5 Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
Adenocarcinoma of the Prostate · Stage II Prostate Cancer · Stage III Prostate Cancer
Primary: Efficacy as Assessed by Number of Patients With Changes Across Transcript Profiles by Microarray Analysis in Prostate Cancer Specimens, Specifically Those With Complete…